PSTI - Pluristem Therapeutics, Inc. Summary, Stock Quote and News | Benzinga

Skip to main content

Market Overview

3.950 0.08 (2.07%)

Data as of May 09, 2021

Prev. Close 3.87
Price Open 3.8
Volume 221,638
Day's Range 3.76 - 4.1
52 Wk Range 3.73 - 12.15
50 Day Moving Avg. 4.84
PE Ratio
Shares Outstanding 31.74M
Market Cap 125.37M

Trade PSTI stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Shanthi RexalineFri, 07 May 2021 07:40:07 -0400
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know Rachit VatsFri, 07 May 2021 02:22:04 -0400
Stocks That Hit 52-Week Lows On Thursday Benzinga InsightsThu, 06 May 2021 10:05:03 -0400
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip Rachit VatsThu, 06 May 2021 01:16:06 -0400
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Shanthi RexalineWed, 05 May 2021 07:43:28 -0400
Cathie Wood Loaded Up Further On Skillz On Earnings Day Rachit VatsWed, 05 May 2021 02:51:42 -0400
Stocks That Hit 52-Week Lows On Tuesday Benzinga InsightsTue, 04 May 2021 10:12:44 -0400
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 Benzinga InsightsTue, 04 May 2021 10:09:11 -0400
Alliance Global Partners Initiates Coverage On Pluristem Therapeutics with Buy Rating, Announces Price Target of $12.5 Benzinga NewsdeskTue, 04 May 2021 08:52:50 -0400
Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD — Also Adds Skillz Rachit VatsTue, 04 May 2021 00:17:10 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans Globe NewswireApr 29, 2021
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering Globe NewswireFeb 02, 2021
Pluristem Announces Uplisting to the Nasdaq Global Market® Globe NewswireJan 27, 2021
Pluristem Announces Appointments of Two Directors to Board Globe NewswireJan 06, 2021
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico Globe NewswireDec 29, 2020
Elliott Management Nominates Independent, Highly Qualified Trustee Candidates to the Board of Public Storage PRNewswireDec 14, 2020
Elliott Management Nominates Independent, Highly Qualified Trustee Candidates to the Board of Public Storage PRNewswireDec 14, 2020
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study Globe NewswireDec 09, 2020
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting Globe NewswireNov 18, 2020
World Experts in Infectious Diseases & Critical Care Form Pluristem's COVID-19 Steering Committee Globe NewswireOct 20, 2020
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Pluristem shares rise 13% on promising PLX-R18 results in hematology program Seeking AlphaApr 29, 2021
Pluristem expands COVID-19 program in Mexico Seeking AlphaDec 29, 2020
Pluristem plunges 42% as CLI trial unlikely to meet primary endpoint, study terminated Seeking AlphaDec 09, 2020
STMicroelectronics, FireEye leads premarket losers' pack Seeking AlphaDec 09, 2020
Pluristem - Moment Of Truth Seeking AlphaDec 08, 2020
Seeking Alpha Catalyst Watch Seeking AlphaDec 04, 2020
Regeneron's Ebola Approval, And Other News: The Good, Bad And Ugly Of Biopharma Seeking AlphaOct 18, 2020
Pluristem on go with cohort II of mid-stage chronic graft vs host disease study Seeking AlphaOct 13, 2020
Pluristem to conduct Phase II COVID-19 European trial in Israel Seeking AlphaOct 06, 2020
Pluristem to complete enrollment in Phase II COVID-19 study in Q1 2021 Seeking AlphaSep 15, 2020
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Powered by StockSnips

60.02% Positive

Earnings View Earnings

Q2 2021	EST	Actual	Surprise
EPS:	Expected 2021-02-08
Rev:	Expected 2021-02-08

Q3 2021	EST	Actual	Surprise
EPS:	Expected 2021-05-21
Rev:	Expected 2021-05-21

Start Investing

The Best Online Stock Trading Brokers

Best Free Stock Trading Brokers

Best Forex Brokers

Best Futures Brokers

How to Invest in Real Estate

Best Day Trading Courses